Japanese Society of Regenerative Medicine

Japanese Society of Regenerative Medicine
Name	Japanese Society of Regenerative Medicine
Native name	日本再生医療学会
Founded	1999
Headquarters	Tokyo

Japanese Society of Regenerative Medicine is a professional association established to promote research, clinical translation, and education in regenerative medicine and stem cell therapy in Japan. The society engages with academic institutions, regulatory bodies, and industry stakeholders to advance tissue engineering, cell therapy, and regenerative biology. Its membership spans clinicians, researchers, and corporate partners connected to universities, hospitals, and research institutes across Japan and internationally.

History

The society was formed in the context of breakthroughs at institutions such as University of Tokyo, Kyoto University, Osaka University, Keio University, and Tohoku University, and amid policy developments involving the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Early milestones paralleled discoveries by researchers associated with Shinya Yamanaka, Harvard University, Gladstone Institutes, Riken, and RIKEN Center for Developmental Biology, while scientific dialogues included participants from Cambridge University, Stanford University, Massachusetts Institute of Technology, Harvard Medical School, and Cold Spring Harbor Laboratory. The society’s timeline intersects with landmark events like the revision of the Act on the Safety of Regenerative Medicine, deliberations in the Diet of Japan, and international meetings involving World Health Organization, International Society for Stem Cell Research, and European Medicines Agency representatives.

Organization and Membership

Governance mirrors structures found at institutions such as National Institutes of Health, Wellcome Trust, Max Planck Society, Howard Hughes Medical Institute, and European Molecular Biology Organization, with councils and committees modeled after those in American Society for Cell Biology and British Society for Cell Biology. Membership categories include clinicians from National Cancer Center Hospital, researchers from Riken BRC, industry representatives from companies like Takeda Pharmaceutical Company, AstraZeneca, Novo Nordisk, and innovators from startups incubated through JST and METI programs. The society collaborates with academic departments at Hokkaido University, Nagoya University, Kyushu University, Kobe University, and Tokyo Medical and Dental University, and engages award mechanisms analogous to Lasker Award and Nobel Prize recognitions, while liaising with ethics committees similar to those at Johns Hopkins University and UCL.

Activities and Programs

Programs include educational initiatives comparable to workshops at Cold Spring Harbor Laboratory, training modules like those at EMBO, and fellowship schemes reminiscent of Gairdner Foundation and Fulbright Program exchanges. The society runs clinical guideline development similar to protocols from American Medical Association and Royal College of Physicians, accreditation processes informed by Pharmaceuticals and Medical Devices Agency standards, and patient-safety campaigns aligning with World Health Organization frameworks. It organizes translational pipelines linking discovery labs such as Salk Institute and Broad Institute with biotech partners like Celltrion, Fujifilm, Daiichi Sankyo, and venture investors represented by SoftBank-affiliated funds. Outreach projects involve hospitals like St. Luke's International Hospital and Keio University Hospital and patient advocacy groups modeled after Cancer Research UK and Alzheimer's Association.

Conferences and Publications

Annual meetings attract presenters from International Society for Stem Cell Research, Society for Neuroscience, American Association for Cancer Research, European Society of Gene and Cell Therapy, and delegations from NIH. Proceedings and journals published by the society parallel formats used by Nature, Cell, Science, The Lancet, and Journal of Clinical Investigation, and feature contributions from authors affiliated with Cedars-Sinai Medical Center, Mayo Clinic, Massachusetts General Hospital, Karolinska Institutet, and University College London. Special sessions convene panels including regulators from Pharmaceuticals and Medical Devices Agency, ethicists from The Hastings Center, and patent experts referencing precedents from United States Patent and Trademark Office and European Patent Office.

Research and Policy Contributions

The society has influenced policy debates alongside stakeholders such as Ministry of Economy, Trade and Industry, Cabinet Office (Japan), Diet of Japan committees, and advisory bodies like Science Council of Japan. It has provided expert input on frameworks comparable to the Act on the Safety of Regenerative Medicine and on reimbursement discussions involving Japan Medical Association and payers analogous to National Health Service (England). Research outputs span collaborations with laboratories at Riken Center for Biosystems Dynamics Research, Keio University School of Medicine, Kyoto University Hospital, and multinational consortia including investigators from NIH, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, and Institut Pasteur. The society’s policy white papers reference international guidelines from World Health Organization, International Society for Stem Cell Research, and regulatory experiences at Food and Drug Administration and European Medicines Agency.

International Collaborations

The society maintains partnerships with organizations such as International Society for Stem Cell Research, Asia Pacific Regenerative Medicine Network, European Society for Gene and Cell Therapy, American Society for Cell Biology, and regional bodies including Korean Society for Stem Cell Research and Chinese Society for Cell Biology. Collaborative projects have linked researchers from Stanford University, Harvard Medical School, Oxford University, Cambridge University, Max Planck Institute for Molecular Biomedicine, Karolinska Institutet, University of Toronto, and University of Melbourne in multinational clinical trials and harmonization efforts with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use standards. Exchange programs involve institutions like RIKEN, National Institutes of Health, Wellcome Trust, Alexander von Humboldt Foundation, and European Commission research initiatives.

Category:Medical societies in Japan